Results of MTT assays showed that the sensitivity of CD133+ HepG2 and Huh7 cells to cisplatin was obviously lower than the CD133- HCC cells when they were under the equal concentrations of cisplatin (Figure 1C). This evidence concerns the gene PROM1 and hepatocellular carcinoma.